Press Releases

The Roswell Park Alliance Foundation is proud to announce the hiring of Kate Kaming into a newly created role for the organization. Kaming will serve as the Vice President for Development for the Roswell Park Alliance Foundation and the Senior Executive Director for Grateful Patient Philanthropy for Roswell Park Comprehensive Cancer Center.

A new study published in the journal Nature Communications, led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, of Roswell Park, highlights the therapeutic impact of CDK2 inhibitors as treatment for cancers including some breast and pancreatic tumors.

Roswell Park Comprehensive Cancer Center announced the naming of the New Era Cap Foundation Elevate Salon. The naming of the salon, located in Roswell Park’s downtown campus, comes with a $1 million endowed gift from the New Era Cap Foundation and New Era Cap, LLC.

Roswell Park experts will share new discoveries and insights at the 2025 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Feb. 12-15 in Honolulu.

Registration is now open for the 30th anniversary Ride for Roswell, to be held June 27-28 at the University at Buffalo’s North Campus. Presented by West Herr Automotive Group, the event has grown into one of the largest fundraising events in the country.

Roswell Park was honored with two eHealthcare Leadership Awards at the 25th annual Healthcare Internet Conference, earning a Platinum Award for Best Email Content and a Silver Award for Best Internet Site.

CAR T-cell therapy, an emerging personalized cancer treatment, is offering patients new hope for the possibility of long-term remission. Roswell Park is at the forefront of this new approach, with one of the largest facilities in the country dedicated to improving and expanding this type of cancer treatment.

Researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center and the Icahn School of Medicine at Mount Sinai have found that bacterial vaginosis actually consists of two subtypes — one of which significantly increases the risk of developing chlamydia infections.

A team led by Anna Bianchi-Smiraglia has identified a previously unknown cause of resistance to doxorubicin, pointing to a new strategy for treating aggressive "triple-negative" breast cancer.